Literature DB >> 27510420

Liver X receptors: from cholesterol regulation to neuroprotection-a new barrier against neurodegeneration in amyotrophic lateral sclerosis?

Kevin Mouzat1,2,3, Cédric Raoul4, Anne Polge5, Jovana Kantar5,4, William Camu6,4,7, Serge Lumbroso5,6,4.   

Abstract

Cholesterol plays a central role in numerous nervous system functions. Cholesterol is the major constituent of myelin sheaths, is essential for synapse and dendrite formation, axon guidance as well as neurotransmission. Among regulators of cholesterol homeostasis, liver X receptors (LXRs), two members of the nuclear receptor superfamily, play a determinant role. LXRs act as cholesterol sensors and respond to high intracellular cholesterol concentration by decreasing plasmatic and intracellular cholesterol content. Beyond their cholesterol-lowering role, LXRs have been proposed as regulators of immunity and anti-inflammatory factors. Dysregulation of cholesterol metabolism combined to neuroinflammatory context have been described in neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). ALS is characterized by the progressive loss of motoneurons in the brain and spinal cord, leading to severe paralytic condition and death of patients in a median time of 3 years. Motoneuron degeneration is accompanied by chronic neuroinflammatory response, involving microglial and astrocytic activation, infiltration of blood-derived immune cells and release of pro-inflammatory factors. We propose to discuss here the role of LXRs as a molecular link between the central nervous system cholesterol metabolism, neuroinflammation, motoneuron survival and their potential as promising therapeutic candidates for ALS therapy.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; Astrocytes; Cholesterol; Liver X receptors; Microglia; Neuroinflammation

Mesh:

Substances:

Year:  2016        PMID: 27510420     DOI: 10.1007/s00018-016-2330-y

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  85 in total

1.  Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters.

Authors:  K E Berge; H Tian; G A Graf; L Yu; N V Grishin; J Schultz; P Kwiterovich; B Shan; R Barnes; H H Hobbs
Journal:  Science       Date:  2000-12-01       Impact factor: 47.728

Review 2.  Innate immunity in Alzheimer's disease.

Authors:  Michael T Heneka; Douglas T Golenbock; Eicke Latz
Journal:  Nat Immunol       Date:  2015-03       Impact factor: 25.606

Review 3.  A basic overview of multiple sclerosis immunopathology.

Authors:  N Grigoriadis; V van Pesch
Journal:  Eur J Neurol       Date:  2015-10       Impact factor: 6.089

4.  Hypermetabolism in ALS: correlations with clinical and paraclinical parameters.

Authors:  Jean-Claude Desport; Frédéric Torny; Mathieu Lacoste; Pierre-Marie Preux; Philippe Couratier
Journal:  Neurodegener Dis       Date:  2005       Impact factor: 2.977

Review 5.  Mechanisms underlying inflammation in neurodegeneration.

Authors:  Christopher K Glass; Kaoru Saijo; Beate Winner; Maria Carolina Marchetto; Fred H Gage
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

Review 6.  Prognostic factors in ALS: A critical review.

Authors:  Adriano Chiò; Giancarlo Logroscino; Orla Hardiman; Robert Swingler; Douglas Mitchell; Ettore Beghi; Bryan G Traynor
Journal:  Amyotroph Lateral Scler       Date:  2009 Oct-Dec

7.  Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants.

Authors:  Arie Katz; Chandrasekhar Udata; Elyssa Ott; Lisa Hickey; Michael E Burczynski; Peter Burghart; Ole Vesterqvist; Xu Meng
Journal:  J Clin Pharmacol       Date:  2009-04-27       Impact factor: 3.126

Review 8.  Effects of oxysterols on the blood-brain barrier: implications for Alzheimer's disease.

Authors:  Fabien Gosselet; Julien Saint-Pol; Laurence Fenart
Journal:  Biochem Biophys Res Commun       Date:  2013-11-22       Impact factor: 3.575

9.  Synthesis of the oxysterol, 24(S), 25-epoxycholesterol, parallels cholesterol production and may protect against cellular accumulation of newly-synthesized cholesterol.

Authors:  Jenny Wong; Carmel M Quinn; Andrew J Brown
Journal:  Lipids Health Dis       Date:  2007-04-05       Impact factor: 3.876

Review 10.  Control of Inflammatory Responses: a New Paradigm for the Treatment of Chronic Neuronal Diseases.

Authors:  Joo Hong Woo; Jee Hoon Lee; Hyunmi Kim; Soo Jung Park; Eun-Hye Joe; Ilo Jou
Journal:  Exp Neurobiol       Date:  2015-05-11       Impact factor: 3.261

View more
  5 in total

Review 1.  Exploring mitochondrial cholesterol signalling for therapeutic intervention in neurological conditions.

Authors:  Radha Desai; Michelangelo Campanella
Journal:  Br J Pharmacol       Date:  2019-08-09       Impact factor: 8.739

Review 2.  Regulation of Brain Cholesterol: What Role Do Liver X Receptors Play in Neurodegenerative Diseases?

Authors:  Kevin Mouzat; Aleksandra Chudinova; Anne Polge; Jovana Kantar; William Camu; Cédric Raoul; Serge Lumbroso
Journal:  Int J Mol Sci       Date:  2019-08-08       Impact factor: 5.923

3.  Cerebrotendinous xanthomatosis with peripheral neuropathy: a clinical and neurophysiological study in Chinese population.

Authors:  Shu Zhang; Wei Li; Rui Zheng; Bing Zhao; Yongqing Zhang; Dandan Zhao; Cuiping Zhao; Chuanzhu Yan; Yuying Zhao
Journal:  Ann Transl Med       Date:  2020-11

4.  T0901317, an Agonist of Liver X Receptors, Attenuates Neuronal Apoptosis in Early Brain Injury after Subarachnoid Hemorrhage in Rats via Liver X Receptors/Interferon Regulatory Factor/P53 Upregulated Modulator of Apoptosis/Dynamin-1-Like Protein Pathway.

Authors:  Jiaxing Dai; Shancai Xu; Takeshi Okada; Yu Liu; Gang Zuo; Jiping Tang; John H Zhang; Huaizhang Shi
Journal:  Oxid Med Cell Longev       Date:  2021-05-28       Impact factor: 7.310

Review 5.  Integrating Thyroid Hormone Signaling in Hypothalamic Control of Metabolism: Crosstalk Between Nuclear Receptors.

Authors:  Soumaya Kouidhi; Marie-Stéphanie Clerget-Froidevaux
Journal:  Int J Mol Sci       Date:  2018-07-11       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.